302 related articles for article (PubMed ID: 35089585)
1. Middle East Respiratory Syndrome coronavirus vaccine development: updating clinical studies using platform technologies.
Choi JA; Kim JO
J Microbiol; 2022 Mar; 60(3):238-246. PubMed ID: 35089585
[TBL] [Abstract][Full Text] [Related]
2. Microneedle array delivered recombinant coronavirus vaccines: Immunogenicity and rapid translational development.
Kim E; Erdos G; Huang S; Kenniston TW; Balmert SC; Carey CD; Raj VS; Epperly MW; Klimstra WB; Haagmans BL; Korkmaz E; Falo LD; Gambotto A
EBioMedicine; 2020 May; 55():102743. PubMed ID: 32249203
[TBL] [Abstract][Full Text] [Related]
3. ChAdOx1 and MVA based vaccine candidates against MERS-CoV elicit neutralising antibodies and cellular immune responses in mice.
Alharbi NK; Padron-Regalado E; Thompson CP; Kupke A; Wells D; Sloan MA; Grehan K; Temperton N; Lambe T; Warimwe G; Becker S; Hill AVS; Gilbert SC
Vaccine; 2017 Jun; 35(30):3780-3788. PubMed ID: 28579232
[TBL] [Abstract][Full Text] [Related]
4. Heterologous prime-boost vaccination with adenoviral vector and protein nanoparticles induces both Th1 and Th2 responses against Middle East respiratory syndrome coronavirus.
Jung SY; Kang KW; Lee EY; Seo DW; Kim HL; Kim H; Kwon T; Park HL; Kim H; Lee SM; Nam JH
Vaccine; 2018 Jun; 36(24):3468-3476. PubMed ID: 29739720
[TBL] [Abstract][Full Text] [Related]
5. Cross-Protection against MERS-CoV by Prime-Boost Vaccination Using Viral Spike DNA and Protein.
Choi JA; Goo J; Yang E; Jung DI; Lee S; Rho S; Jeong Y; Park YS; Park H; Moon YH; Park U; Seo SH; Lee H; Lee JM; Cho NH; Song M; Kim JO
J Virol; 2020 Nov; 94(24):. PubMed ID: 32967955
[TBL] [Abstract][Full Text] [Related]
6. Nucleic acid vaccine candidates encapsulated with mesoporous silica nanoparticles against MERS-CoV.
Almansour I; Jermy BR
Hum Vaccin Immunother; 2024 Dec; 20(1):2346390. PubMed ID: 38691025
[TBL] [Abstract][Full Text] [Related]
7. Advances in mRNA and other vaccines against MERS-CoV.
Tai W; Zhang X; Yang Y; Zhu J; Du L
Transl Res; 2022 Apr; 242():20-37. PubMed ID: 34801748
[TBL] [Abstract][Full Text] [Related]
8. Recombinant Receptor-Binding Domains of Multiple Middle East Respiratory Syndrome Coronaviruses (MERS-CoVs) Induce Cross-Neutralizing Antibodies against Divergent Human and Camel MERS-CoVs and Antibody Escape Mutants.
Tai W; Wang Y; Fett CA; Zhao G; Li F; Perlman S; Jiang S; Zhou Y; Du L
J Virol; 2017 Jan; 91(1):. PubMed ID: 27795425
[TBL] [Abstract][Full Text] [Related]
9. Single-Dose, Intranasal Immunization with Recombinant Parainfluenza Virus 5 Expressing Middle East Respiratory Syndrome Coronavirus (MERS-CoV) Spike Protein Protects Mice from Fatal MERS-CoV Infection.
Li K; Li Z; Wohlford-Lenane C; Meyerholz DK; Channappanavar R; An D; Perlman S; McCray PB; He B
mBio; 2020 Apr; 11(2):. PubMed ID: 32265331
[TBL] [Abstract][Full Text] [Related]
10. Antibodies and vaccines against Middle East respiratory syndrome coronavirus.
Xu J; Jia W; Wang P; Zhang S; Shi X; Wang X; Zhang L
Emerg Microbes Infect; 2019; 8(1):841-856. PubMed ID: 31169078
[TBL] [Abstract][Full Text] [Related]
11. A Highly Immunogenic and Protective Middle East Respiratory Syndrome Coronavirus Vaccine Based on a Recombinant Measles Virus Vaccine Platform.
Malczyk AH; Kupke A; Prüfer S; Scheuplein VA; Hutzler S; Kreuz D; Beissert T; Bauer S; Hubich-Rau S; Tondera C; Eldin HS; Schmidt J; Vergara-Alert J; Süzer Y; Seifried J; Hanschmann KM; Kalinke U; Herold S; Sahin U; Cichutek K; Waibler Z; Eickmann M; Becker S; Mühlebach MD
J Virol; 2015 Nov; 89(22):11654-67. PubMed ID: 26355094
[TBL] [Abstract][Full Text] [Related]
12. Effect of Fc Fusion on Folding and Immunogenicity of Middle East Respiratory Syndrome Coronavirus Spike Protein.
Chun J; Cho Y; Park KH; Choi H; Cho H; Lee HJ; Jang H; Kim KH; Oh YK; Kim YB
J Microbiol Biotechnol; 2019 May; 29(5):813-819. PubMed ID: 30982320
[TBL] [Abstract][Full Text] [Related]
13. An overview of Middle East respiratory syndrome coronavirus vaccines in preclinical studies.
Zhang N; Shang J; Li C; Zhou K; Du L
Expert Rev Vaccines; 2020 Sep; 19(9):817-829. PubMed ID: 32842811
[TBL] [Abstract][Full Text] [Related]
14. The recombinant N-terminal domain of spike proteins is a potential vaccine against Middle East respiratory syndrome coronavirus (MERS-CoV) infection.
Jiaming L; Yanfeng Y; Yao D; Yawei H; Linlin B; Baoying H; Jinghua Y; Gao GF; Chuan Q; Wenjie T
Vaccine; 2017 Jan; 35(1):10-18. PubMed ID: 27899228
[TBL] [Abstract][Full Text] [Related]
15. Development of virus-like particles-based vaccines against coronaviruses.
Yong CY; Liew WPP; Ong HK; Poh CL
Biotechnol Prog; 2022 Nov; 38(6):e3292. PubMed ID: 35932092
[TBL] [Abstract][Full Text] [Related]
16. Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial.
Folegatti PM; Bittaye M; Flaxman A; Lopez FR; Bellamy D; Kupke A; Mair C; Makinson R; Sheridan J; Rohde C; Halwe S; Jeong Y; Park YS; Kim JO; Song M; Boyd A; Tran N; Silman D; Poulton I; Datoo M; Marshall J; Themistocleous Y; Lawrie A; Roberts R; Berrie E; Becker S; Lambe T; Hill A; Ewer K; Gilbert S
Lancet Infect Dis; 2020 Jul; 20(7):816-826. PubMed ID: 32325038
[TBL] [Abstract][Full Text] [Related]
17. DNA vaccine encoding Middle East respiratory syndrome coronavirus S1 protein induces protective immune responses in mice.
Chi H; Zheng X; Wang X; Wang C; Wang H; Gai W; Perlman S; Yang S; Zhao J; Xia X
Vaccine; 2017 Apr; 35(16):2069-2075. PubMed ID: 28314561
[TBL] [Abstract][Full Text] [Related]
18. Blocking transmission of Middle East respiratory syndrome coronavirus (MERS-CoV) in llamas by vaccination with a recombinant spike protein.
Rodon J; Okba NMA; Te N; van Dieren B; Bosch BJ; Bensaid A; Segalés J; Haagmans BL; Vergara-Alert J
Emerg Microbes Infect; 2019; 8(1):1593-1603. PubMed ID: 31711379
[TBL] [Abstract][Full Text] [Related]
19. A chimeric MERS-CoV virus-like particle vaccine protects mice against MERS-CoV challenge.
Park JE; Kim JH; Park JY; Jun SH; Shin HJ
Virol J; 2022 Jun; 19(1):112. PubMed ID: 35761402
[TBL] [Abstract][Full Text] [Related]
20. Consensus summary report for CEPI/BC March 12-13, 2020 meeting: Assessment of risk of disease enhancement with COVID-19 vaccines.
Lambert PH; Ambrosino DM; Andersen SR; Baric RS; Black SB; Chen RT; Dekker CL; Didierlaurent AM; Graham BS; Martin SD; Molrine DC; Perlman S; Picard-Fraser PA; Pollard AJ; Qin C; Subbarao K; Cramer JP
Vaccine; 2020 Jun; 38(31):4783-4791. PubMed ID: 32507409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
